Zacks Research Brokers Raise Earnings Estimates for Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Analysts at Zacks Research increased their Q1 2025 earnings estimates for Bio-Rad Laboratories in a report issued on Monday, April 15th. Zacks Research analyst R. Anand now expects that the medical research company will post earnings of $2.39 per share for the quarter, up from their previous forecast of $2.35. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $10.41 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q3 2025 earnings at $3.83 EPS.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.17. The business had revenue of $681.18 million for the quarter, compared to analyst estimates of $685.00 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. Bio-Rad Laboratories's revenue for the quarter was down 6.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.31 earnings per share.

Several other brokerages have also weighed in on BIO. Citigroup lowered shares of Bio-Rad Laboratories from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $400.00 to $365.00 in a report on Wednesday, April 3rd. Royal Bank of Canada dropped their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an "outperform" rating on the stock in a report on Friday, February 16th. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a report on Friday, April 5th. Finally, UBS Group upped their price objective on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a "buy" rating in a report on Friday, February 16th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $468.00.

Bio-Rad Laboratories Stock Down 0.7 %

Shares of NYSE BIO traded down $1.97 during trading on Wednesday, hitting $290.78. 214,091 shares of the company traded hands, compared to its average volume of 199,335. The business's fifty day moving average is $331.66 and its 200 day moving average is $321.00. Bio-Rad Laboratories has a fifty-two week low of $261.59 and a fifty-two week high of $489.36. The firm has a market capitalization of $8.29 billion, a price-to-earnings ratio of -13.53 and a beta of 0.87. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83.

Institutional Trading of Bio-Rad Laboratories

A number of institutional investors have recently modified their holdings of BIO. Sound Income Strategies LLC purchased a new stake in Bio-Rad Laboratories in the 1st quarter worth approximately $38,000. Ballentine Partners LLC purchased a new stake in Bio-Rad Laboratories in the 1st quarter worth approximately $213,000. Park Avenue Securities LLC lifted its stake in Bio-Rad Laboratories by 10.2% in the 1st quarter. Park Avenue Securities LLC now owns 2,220 shares of the medical research company's stock worth $768,000 after purchasing an additional 205 shares in the last quarter. Polianta Ltd lifted its stake in Bio-Rad Laboratories by 22.2% in the 1st quarter. Polianta Ltd now owns 3,300 shares of the medical research company's stock worth $1,141,000 after purchasing an additional 600 shares in the last quarter. Finally, Fulton Bank N.A. purchased a new stake in Bio-Rad Laboratories in the 1st quarter worth approximately $243,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Bio-Rad Laboratories

In related news, EVP Michael Crowley sold 3,000 shares of the company's stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the sale, the executive vice president now directly owns 6,942 shares in the company, valued at approximately $2,332,512. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 17.50% of the stock is currently owned by corporate insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.